Vivek Subbiah: Precision Dosing IS Precision Oncology

Vivek Subbiah shared a post on X:

“Pleased to share the pre-proof version of the editorial commentary just published ESMO flagship journal, Annals of Oncology. Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology.”

Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology

Authors: Vivek Subbiah, MD

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.